Luminex Licenses xMAP to Bayer Diagnostics
Luminex of Austin, Texas, licensed its xMAP technology to Bayer Diagnostics and entered into a multi-year agreement to develop a cellular analyzer, the company said. Bayer will pay Luminex a one-time licensing fee and royalities to develop and distribute in-vitro diagnostic products based on xMAP.
BioTrove Takes $5.25 million VC Investment
BioTrove of Cambridge, Mass., raised $5.25 million in a private-equity financing announced last week.
The round was led by Catalyst Health and Technol ogy Partners, and includes investments from CB Health Ventures, Zero Stage Capital and BioFrontier Partners, a Japanese venture capital firm.
The company, founded in January 1997 has created nanofluidics technology in its Living Chip, a micro-scale high-throughput array, and Lab-on-a-tape, another high-throughput analysis product.
Bioforce Takes $2M in French Capital
Société Genérale Asset Management of Paris will invest $2 million in BioForce Nanosciences of Ames, Iowa, the company announced this week.
BioForce recently received a $500,000 Phase II Small Business Innovation Research grant from the NIH to further develop its NanoArrayer technique for creating ultra-miniaturized microarrays. BioForce has a partnership with Lance Liotta and Emanuel Petricoin of the NCI-Food and Drug Administration proteomics program to apply the NanoArray technology to protein chips.
Molecular Staging Awarded SBIR Grants
Molecular Staging of New Haven, Conn., received $100,000 in two SBIR grants. The company was awarded an SBIR grant from the Department of Energy (DOE) to develop methods for microbial DNA amplification using its proprietary Multiple Displacement Amplification (MDA) technology. The company also received an additional grant to develop a biomarker chip for enhanced diagnosis of osteoarthritis.
Rockefeller Offers Microarray Course
Richard Simon, Jurg Ott, and Yaning Yang of the Laboratory of Statistical Genetics of Rockefeller Univer sity will conduct a 3-day course on Design and Analysis of DNA Microarray Studies on Jan. 23-25, 2003 at the university's in New York campus. The course is for scientists who want an in-depth understanding of analysis methods and experimental design strategies. Participants will be provided with computers and BRB-ArrayTools software, which is available from the Simon lab at the NCI, http://linus.nic.nigh.gov/~brb. Problem sets will be assigned. Registration is limited to 25.
Trading Spaces in U.K., Virginia
SmartBead, a Cambridge, England, based company that creates an array technology based on barcoded microparticles, has won a year's rent and services in a Fairfax County, Va., biotechnology incubator in a marketing play organized by the Fairfax County Economic Development Authority.
The agency devised a two-way exchange of rent and services between the Fairfax County BioAcceleraor and the York Science Park.
Enlightened Technologies Associates, a company that has a product to counteract sleep disorders, won free rent in the York, U.K., property.
MWG-Biotech Resets Forecast Downwards
MWG-Biotech of Ebersberg, Germany, said last week that it was revising its revenue expectations to €52 million from the €64 million previously stated. The company also said it plans to take a write-down of €8.4 million on inventory and development.
The company said it was adjusting from “misguided product policy of the last few years.” The company, which has eliminated 60 percent of the jobs in its genomic technology division, said it plans to relaunch its platform in the first quarter of 2003.
UAB Awarded $2.2 million NSF Grant
Grier Page, assistant professor of biostatistics, and Stephen Barnes, professor of pharmacology, of the University of Alabama at Birmingham have received a four-year, $2.2 million grant from the National Science Foundation to develop and evaluate scientific methods for use of microarray technology to study gene expression in the soybean genome, the university announced this week.
LICR Extends Lynx GENE Analysis
Lynx Therapeutics of Hayward, Calif., has completed initial gene expression analysis for the Ludwig Institute for Cancer Research (LICR), which will extend the studies to include additional samples from LICR branches around the world, Lynx said.